Shinichi Tamura is now serving in a new position at Sosei Group Corp.

Jan 02, 2019
Board and Executive Moves
Background Information
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its operations are carried out through the following segments: Pharmaceutical Development Business. The Pharmaceutical Development Business segment engages in the research, development and sales of medicines; management of regenerative medical funds; investment in bio venture companies related to regenerative medicines; overseas development by licensing; promotions of commercialization; structural analysis of GPCR; initial lead compound creation; candidate search by proprietary StaR (Stabilised Receptor) technology; as well as structural base of new drugs using GPCR related basic technology drug discovery; screening and promotions of antibody drug research and development. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.